Core Viewpoint - Fengyuan Pharmaceutical's stock price has increased by 0.99% to 7.14 yuan, with a total market capitalization of 3.318 billion yuan and a price-to-earnings ratio of 21.82 times [1] Group 1: Financial Performance - The company reported that its revenue contributions from drug manufacturing and retail distribution are 46.65% and 49.75% respectively for the year 2024 [1] - The total trading volume for the day was 117 million yuan, with the stock reaching a high of 7.16 yuan and a low of 7.02 yuan during trading [1] Group 2: Share Transfer Announcement - On August 11, the company announced that its controlling shareholder, Fengyuan Group, along with its concerted parties, plans to transfer 23.6986 million shares, representing 5.1% of the total share capital, to Hainan Guihe Dayi Investment Partnership through a private agreement [1] - The transfer price is set at 6.72 yuan per share, totaling 159 million yuan, with the acquiring party expressing confidence in the company's future development [1]

Core Viewpoint - Fengyuan Pharmaceutical (000153) announced the transfer of 23.6986 million shares, representing 5.1% of the total share capital, from its controlling shareholder Anhui Fengyuan Group Co., Ltd. to Hainan Guihe Dayi Investment Partnership (Limited Partnership) at a price of 6.72 yuan per share, totaling 159 million yuan, indicating recognition of the company's future development prospects and investment value by Guihe Dayi [1] Group 1 - The controlling shareholder and its concerted party plan to transfer shares through an agreement [1] - The total number of shares being transferred is 23.6986 million, which constitutes 5.1% of the company's total share capital [1] - The agreed transfer price is 6.72 yuan per share, leading to a total transaction value of 159 million yuan [1]

格隆汇8月11日丨丰原药业(000153.SZ)公布，公司控股股东安徽丰原集团有限公司(简称"丰原集团")及 其一致行动人马鞍山丰原企业管理有限公司(简称"马鞍山丰原")拟通过协议转让方式，向海南贵和达毅 投资合伙企业(有限合伙)(简称"贵和达毅")转让其持有的公司股份合计23,698,554股，占公司总股本的 5.10%。转让价格为6.72元/股，股份转让总价款合计为人民币1.59亿元。 ...

Core Viewpoint - Fengyuan Pharmaceutical (000153) announced on August 11 that its controlling shareholder, Fengyuan Group, along with its concerted party, Ma'anshan Fengyuan Enterprise Management Co., Ltd., signed a share transfer agreement with Hainan Guihe Dayi Investment Partnership (Limited Partnership) to transfer a total of 5.1% of the company's shares at a price of 6.72 yuan per share, amounting to a total consideration of 159 million yuan [1]. Group 1 - The share transfer involves a total of 5.1% of Fengyuan Pharmaceutical's shares [1]. - The agreed transfer price is 6.72 yuan per share [1]. - The total transaction value is 159 million yuan [1].

格隆汇8月11日丨丰原药业(000153.SZ)公布，公司控股股东安徽丰原集团有限公司(简称"丰原集团")及 其一致行动人马鞍山丰原企业管理有限公司(简称"马鞍山丰原")拟通过协议转让方式，向海南贵和达毅 投资合伙企业(有限合伙)(简称"贵和达毅")转让其持有的公司股份合计23,698,554股，占公司总股本的 5.10%。转让价格为6.72元/股，股份转让总价款合计为人民币1.59亿元。 ...

二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定， 本报告书已全面披露信息披露义务人在安徽丰原药业股份有限公司拥有权益的 股份变动情况。截至本报告书签署之日，除本报告书披露的信息外，上述信息披 露义务人没有通过任何其他方式增加或减少其在安徽丰原药业股份有限公司中 拥有权益的股份。 四、本次权益变动是根据本报告所载明的资料进行的。除本信息披露义务人 外，没有委托或者授权其它任何人提供未在本报告书列载的信息和对本报告书做 出任何解释或者说明。 五、本次权益变动尚需按照深圳证券交易所协议转让相关规定履行合规性 确认等程序，并在中国证券登记结算有限责任公司深圳分公司办理股份过户登记 手续。 安徽丰原药业股份有限公司 简式权益变动报告书 上市公司名称：安徽丰原药业股份有限公司 股票上市地点：深圳证券交易所 股票简称：丰原药业 股票代码：000153 信息披露义务人一：安徽丰原集团有限公司 住所：安徽省蚌埠市禹会区胜利西路777号 通讯地址：安徽省蚌埠市禹会区胜利西路777号 信 ...

Core Points - The report details a share transfer agreement where Hainan Guihe Dayi Investment Partnership (Limited Partnership) acquires 23,698,554 shares of Anhui Fengyuan Pharmaceutical Co., Ltd., representing 5.1% of the company's total share capital [1][4][10] - The share transfer is based on mutual agreement between the parties involved, with the acquirer recognizing the company's future development prospects and investment value [4] - The total transfer price for the shares is approximately RMB 159.25 million, with specific amounts allocated to each transferring party [7][8] Group 1: Share Transfer Details - The share transfer agreement was signed on August 11, 2025, and involves two parties: Anhui Fengyuan Group Co., Ltd. and Ma'anshan Fengyuan Enterprise Management Co., Ltd. [5][6] - The shares being transferred are unrestricted circulating shares, with the breakdown of shares transferred being 21,464,842 from the first party and 2,233,712 from the second party [7] - The acquirer commits to not reducing its stake in the company for 18 months following the completion of the share transfer [4][10] Group 2: Compliance and Legal Aspects - The share transfer must comply with the regulations of the Shenzhen Stock Exchange and requires the completion of share transfer registration with the China Securities Depository and Clearing Corporation [2][8] - The information disclosure obligation party affirms that the report contains no false records, misleading statements, or significant omissions, and accepts legal responsibility for its accuracy [2][9] - The acquirer does not hold any other shares in listed companies that exceed 5% of their issued shares as of the report date [3]

股票简称：丰原药业 股票代码：000153 公告编号：2025-025 安徽丰原药业股份有限公司 关于控股股东及其一致行动人拟协议转让 公司部分股份暨权益变动的提示性公告 公司控股股东及其一致行动人和受让方保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： （一）本次协议转让的基本情况 公司收到丰原集团、马鞍山丰原的通知，获悉上述公司股东于 2025 年 8 月 11 日与贵和达毅签订了《股份转让协议》，协议约定：丰原集团、马鞍山丰原合计将其 持有的上市公司股份 23,698,554 股（占公司总股本的 5.1%）转让给贵和达毅。转让 价格为 6.72 元/股，股份转让总价款合计为人民币 159,254,282.88 元。截至本公告日， 上述股份尚未办理过户登记。具体情况如下： 转让价格 占总股 限公司（以下简称"丰原集团"）及其一致行动人马鞍山丰原企业管理有限公司（简称"马鞍山丰 原"）拟通过协议转让方式，向海南贵和达毅投资合伙企业（有限合伙）（以下简称"贵和达毅" ...

2024年1至12月份，丰原药业的营业收入构成为：药品零售流通占比49.75%，药品生产制造占比 46.65%，其他业务占比2.08%，其他行业占比1.52%。 丰原药业（SZ 000153，收盘价：7.14元）8月11日晚间发布公告称，公司收到丰原集团、马鞍山丰原的 通知，获悉上述公司股东于2025年8月11日与贵和达毅签订了《股份转让协议》，协议约定：丰原集 团、马鞍山丰原合计将其持有的上市公司股份约2370万股（占公司总股本的5.1%）转让给贵和达毅。 转让价格为6.72元/股，股份转让总价款合计为人民币约1.59亿元。截至本公告日，上述股份尚未办理过 户登记。 （文章来源：每日经济新闻） ...

【丰原药业：丰原集团、马鞍山丰原合计将其持有的公司2369.86万股转让给贵和达毅】智通财经8月11 日电，丰原药业(000153.SZ)公告称，公司控股股东安徽丰原集团有限公司及其一致行动人马鞍山丰原 企业管理有限公司拟通过协议转让方式，向海南贵和达毅投资合伙企业（有限合伙）转让其持有的公司 股份合计23,698,554股，占公司总股本的5.10%。本次交易不涉及要约收购，不涉及关联交易，不会导 致公司控制权发生变化，不会对公司治理结构及持续经营产生重大影响。转让价格为6.72元/股，股份 转让总价款合计为人民币1.59亿元。 转自：智通财经 ...